Constipation, a prevalent gastrointestinal disorder, often poses diagnostic and therapeutic challenges in clinical practice. A comprehensive approach is crucial for effective management.
Before initiating treatment for constipation, a thorough clinical evaluation is essential. This includes a detailed patient history, physical examination, and when necessary, specialized tests such as colonic transit studies, anorectal manometry, or defecography. The goal is to differentiate functional constipation from secondary causes and other defecatory disorders.
Management strategies should be individualized, starting with lifestyle modifications, including dietary changes and physical activity. Pharmacological treatment may be considered if these measures are ineffective. Bulk-forming, osmotic, and stimulant laxatives are commonly used. Newer agents such as lubiprostone, linaclotide, and plecanatide can be considered for patients with chronic idiopathic constipation.
In patients with dyssynergic defecation, biofeedback therapy is considered the first-line treatment. It is a non-invasive, safe, and effective therapy that improves symptoms by retraining the pelvic floor muscles.
Surgery should be considered as a last resort, only for patients with severe, refractory constipation, and after careful evaluation. Procedures such as subtotal colectomy and ileorectal anastomosis can provide relief in carefully selected patients.
Understanding the complexities of constipation diagnosis and treatment is key to successful patient management. A comprehensive, patient-centered approach that encompasses lifestyle modifications, pharmacological treatment, and when necessary, biofeedback therapy or surgery, can help untangle the knot of constipation in clinical practice.
1.
Stem Cell Selection Unneeded for SSc Transplant Therapy?
2.
Radiation from CT scans could account for 5% of all cancer cases a year, study suggests
3.
Do I have prostate cancer? Why a simple PSA blood test alone won't give you the answer
4.
In Hemophilia A and B, a Novel Monoclonal Antibody Reduces Bleeding.
5.
Tumor infiltration of major blood vessels, not metastasis, may be primary cause of cancer death
1.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
2.
Emerging Dysregulated Signaling Pathways in Early-Onset Colorectal Cancer
3.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
4.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
5.
Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
3.
A New Era in Managing Cancer-Associated Thrombosis
4.
Navigating the Complexities of Ph Negative ALL - Part IX
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation